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rustration over the fact that pharmacological
treatments for Parkinson’s disease (PD) can only provide
the patient with symptomatic relief for a limited amount
of time (5-15 years) has stimulated clinicians and basic
scientists to seek for alternative treatment methods.Since
the major contributing cause of PD has been found to be
the loss or dysfunction of dopamine (DA)–producing
neurons in the nigrostriatal pathway,an obvious treat-
ment alternative would be to try to replace or protect the
damaged DA neurons.This might be achieved by trans-
planting new DA-producing cells and/or by providing the
endogenous remaining DA neurons with protective
agents such as neurotrophic growth factors.
On the basis of positive results from numerous studies
using animal models for PD,the first clinical transplan-
tation studies for PD started in the mid-1980s and
involved autologous transplantation of catecholamine-
producing adrenal medulla cells.
1,2 Previous basic animal
research involving cell implantation had convincingly
shown encouraging functional effects of intrastriatal
grafts of DA-producing cells
3-5 and these effects have
since been confirmed in a range of animal behavioral
tests.
6,7 It was shown that the observed behavioral effects
are dependent on the survival of DA-producing neurons
within the striatum,since the removal of transplanted tis-
sue
8 or an immune rejection of transplanted neurons
9
reverses the transplant-induced behavioral recovery in
animal studies.In addition,intrastriatal grafting in non-
dopaminergic tissues produces no behavioral effects.
10,11
The results of the first clinical trials using adrenal
medulla graft proved to be quite disappointing because
of the absence of any objective reductions in PD signs,
which was believed to be partly due to very poor graft
survival.The scientific community,however,responded
quickly to this disappointment by adopting the scientifi-
cally more sound approach of transplanting PD patients
with DA neurons, which were obtained from aborted
fetuses.
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Transplantation of human fetal dopamine (DA) neurons
to patients with Parkinson’s disease (PD) has given proof
of the principle that new neurons can survive for at
least a decade, and then functionally integrate and pro-
vide significant symptomatic relief. Unfortunately, the
ethical, technical, and practical limitations of using fetal
DA neurons as the source for cell transplantation in PD,
in combination with the development of unwanted
grafting-related side effects, have put a halt to the
spread of this treatment into clinical practice. Hopefully,
recent advances in the fields of stem cell biology and
adult neurogenesis research will lead to new exciting
ways to better understand and control the biological
parameters necessary for achieving safe and successful
neuronal replacement in PD patients. 
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(e-mail: lars.bjorklund@cgb.ki.se)tinued as small open-label trials.The results from four
centers in Sweden,France,USA,and Canada,including
26 patients,have recently been reviewed by Björklund et
al,
14 and the results of these trials have been reported in
numerous publications.
12,13,15-30These open-label studies
have shown that human fetal DA neurons can survive in
the recipient brain for more than 10 years without being
affected by ongoing disease processes.The neurons show
adequate release of DA into the host
18 and,most impor-
tantly, they gradually provide substantial clinical
improvement with up to 50% to 60% reductions in the
Unified Parkinson’s Disease Rating Scale (UPDRS).
Moreover,the clinical improvements strongly correlate
with recovery of movement-related activation of the host
premotor and supplementary motor cortex.
14
Most of the early transplantation efforts for PD were car-
ried out as open-label trials. These trials gave similar
results and suggested the potential benefits of cell trans-
plantation,but concerns were raised about their validity
because of the relative limited number of patients,the vari-
able inclusion criteria,and the lack of adequate control
groups.In 1992,to circumvent these issues,the National
Institutes of Health (NIH) agreed to sponsor two larger
controlled clinical trials.These were designed as double-
blind clinical trials and even included highly controversial
sham surgeries as placebo controls.The results of the first
trial were published in 2001
31 and the results of the second
trial have recently been reported.
32 To transplantation
enthusiasts,the results were rather disappointing—even
troubling.The first study showed no overall improvement
on a subjective global rating scale;however,some reduc-
tions in UPDRS score were found in patients who had
responded well to L-dopa treatment prior to surgery.
14,31,33
The most troubling result was that 15% of the grafted
patients showed severe dyskinesias as a side effect of treat-
ment.The second study also failed to show any significant
improvements after grafting and,in this study,more than
50% of the patients developed dyskinesias.
32 In spite of the
disappointing and troubling results of these recent NIH
trials,most of the scientists involved seem to agree that
more basic research and clinical trials are needed to be
fully able to evaluate the benefits from this highly novel
and still experimental treatment.A more detailed discus-
sion of these issues can be found in Björklund et al.
14
One issue that becomes very clear from the discussion
about cell transplantation for PD is that the current
method of using fetal DA neurons has major technical and
practical limitations, including the limited and ethically
controversial availability of human fetal DA neurons,and
the potential immunological and virological complications
of using nonhuman species as fetal cell sources.Therefore,
most of the scientific community agree that this approach
now requires a better source of transplantable DA neu-
rons if cell therapy is ever to become a realistic and acces-
sible treatment modality for PD.This review will focus on
the various types of stem or progenitor cells currently
under investigation as potential sources for cell replace-
ment in PD.For additional reading on this subject,I would





Embryonic stem (ES) cells,which were first isolated from
mouse blastocysts in 1981,
36,37 have been shown to prolif-
erate indefinitely in vitro in an undifferentiated state,and
to differentiate into various lineages in response to dif-
ferent cell culture conditions.Current extensive knowl-
edge of cell biology,genetic manipulation,and in vitro
culture methods make mouse ES cells an optimal system
for potential development of unlimited transplantable
cell source with reproducible genetic modification and
cell biological methods.
38 It has been known for several
years that mouse blastocyst–derived cell lines could dif-
ferentiate into teratomas containing cells of neuroecto-
dermal lineage after transplantation of undifferentiated
cells into syngeneic mice.
39 Using retinoic acid (RA)
treatment,Bain et al described the first in vitro protocol
for efficient generation of neurons from ES cells.
40
However,the Bain protocol was not suitable to generate
DA neurons, most probably due to the fact that RA
primes the neural cells towards more “dorsal” pheno-
types.Recently,Barberi et al described several protocols
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SNc substantia nigra compactafor the generation of several kinds of neurons from
mouse ES cells.
41 Interestingly,some reports suggest that
neural differentiation from ES cells may even be a
“default” option occurring unless other cell fates are
actively induced.
42,43 This review will focus on the suc-
cessful derivation of DA neurons from ES cells.
In vivo differentiation of DA neurons from ES cells
The first demonstration of ES cell–derived DA cells after
transplantation came from Deacon et al,
44 when they
showed that ES cells could spontaneously differentiate
into DA neurons when grafted to either the brain or 
the kidney capsule.In this study,high numbers of cells 
(>50 000) were used and the grafts often became very
large teratoma-like grafts that outgrew the target area,
thus making any functional effects impossible to study.
On the basis of the encouraging findings of DA cells in
these large grafts,the protocol used by Deacon et al was
primarily modified by decreasing the number of cells
grafted.This led to smaller primarily neural grafts with
numerous DA neurons, which showed beneficial func-
tional integration in a rat model of PD.
45 Importantly,this
study also highlighted the dangers of using dividing,
undifferentiated ES cells for grafting,since about a quar-
ter of the grafts still developed into teratomas,even when
as few as 1000 ES cells were grafted.
In vitro differentiation of DA neurons from ES cells 
Mouse ES cells
The in vitro derivation of DA neurons from mouse ES
cells was first described by McKay and colleagues at the
NIH.
46They used a five-step protocol in which approxi-
mately 30% (percentage of DA neurons/total neurons)
DA differentiation was obtained using treatment with
fibroblast growth factor 2 (FGF2), sonic hedgehog
(SHH),FGF8,and ascorbic acid.This method for deriva-
tion of DA neurons was then further refined to about
80% DA differentiation through transgenic expression
of Nurr-1 in combination with FGF2,SHH,FGF8,and
ascorbic acid treatment.
47 Using a similar Nurr-1 trans-
genic approach, the McKay group later showed func-
tional effects of such in vitro ES cell–derived DA neu-
rons in a rat model of PD.
48 By differentiating the ES cells
from DA neurons pretransplantation, these authors
claimed that they could avoid the teratoma issue seen
using undifferentiated ES cells.
45 Unfortunately, ter-
atomas can still develop even when cells are prediffer-
entiated in vitro,
49 probably due to contamination of
remaining undifferentiated ES cells within the cultures.
Other protocols for the in vitro derivation of DA neurons
from ES cells have been established. Kawasaki et al
showed that yet unknown soluble factors (named stro-
mal cell–derived inducing activity [SDIA]) from the PA6
stromal cell line could facilitate DA differentiation in
approximately 30% to 35% of the neurons derived from
ES cells;unfortunately,these DA neurons survived very
poorly after grafting into the brain.
50 Barbieri et al used
MS5 stromal feeder cells in combination with SHH,
FGF8,ascorbic acid,and brain-derived neurotrophic fac-
tor (BDNF) treatment to obtain approximately 50% DA
differentiation from normal mouse ES cells
41; similar
results have also been obtained from nuclear trans-
fer–derived ES cells.
41,51 Furthermore,Ying et al described
“significant”DA differentiation using monolayer ES cell
cultures in combination with SHH, FGF8, and FGF2
treatment.
52Thus,many recent reports have now made it
clear that efficient generation (30%-80%) of DA neu-
rons can be achieved from mouse ES cells and that such
cells can survive,integrate,and show functional effects in
rodent models of PD.
45,48
Primate (nonhuman and human) ES cells
On the basis of the encouraging results from mouse ES
cells and Thomson’s successful generation of nonhuman
primate
53,54 and human ES cell lines,
55 several labs started
to investigate the possibilities of making DA neurons from
primate ES cells.Kawasaki et al created DA neurons from
nonhuman primate ES cells using PA6 cells and SDIA,
56
and Vrana et al showed DA differentiation from nonhu-
man primate parthenogenetic stem cells (Cyno-1 cells).
57
The in vitro derivation of a smaller number of DA neurons
from human ES cells was described by three different
groups in 2001.
58-60We are now eagerly awaiting the first
convincing demonstration of human ES cell–derived func-
tional DA neurons in rodent or primate models of PD.
EG cells
Embryonic germ (EG) cell lines are pluripotent, self-
renewing stem cells with many similarities to ES cells.
The establishment of mouse EG cell lines was first
described by Matsui et al
61 when they showed that the
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305addition of basic FGF (bFGF) to primordial germ cell
(PGC) cultures in the presence of membrane-associated
steel factor (SF) and leukemia inhibitory factor (LIF)
enhances the growth of PGC beyond that occurring nor-
mally. In 1998, Shamblott et al created human EG cell
lines after culturing gonadal ridges and mesenteries con-
taining primordial germ cells derived from 5- to 9-week
postfertilization embryos.
62Although it has been shown
that EG cells can differentiate into neurons in vivo,
63 no
studies on DA differentiation have been presented so far.
Unspecified NPCs
Neural progenitor cells (NPCs) are multipotent, self-
renewing cells that can differentiate into neurons,astro-
cytes,and oligodendrocytes.NPCs can be derived from
several regions of the fetal or the adult brain
64,65 and are
usually propagated as free floating clumps of cells, so-
called “neurospheres” in which cells are kept dividing
through stimulation via epidermal growth factor (EGF)
and/or FGF2.A smaller proportion of the NPCs have
been shown to differentiate into DA neurons (defined by
their expression of tyrosine hydroxylase [TH],which is
the rate-limiting enzyme in the DA synthetic pathway)
when replated on extracellular matrix protein–coated
dishes and stimulated to differentiation via conditioned
media
66 or through stimulation with growth factors,such
as interleukins (ILs) and glial cell line–derived neu-
rotrophic factor (GDNF).
67 Unfortunately, although
human NPCs can survive transplantation,they show no
significant behavioral effects in a rat model of PD.
68
Genetically modified NPCs and 
neural cell lines
Using an immortalized cerebellar neuronal cell line
(C17.2),Yang et al showed that such cells could sponta-
neously achieve some DA features after being grafted
into the DA-depleted rat striatum
69;however,others have
shown that most C17.2 cells remain undifferentiated after
transplantation and many downregulate TH expression,
suggesting that positive functional effects are primarily
due to other mechanisms.
70 Previously, using the same
C17.2 cell line in combination with transgenic overex-
pression of Nurr-1,a transcription factor known to be of
importance for the normal development of nigral DA
neurons,
71Wagner et al had shown that such C17.2 cells
could start to express TH when stimulated by condi-
tioned media from midbrain type 1 astrocytes.
72Another
cell line that has been used in animal models for PD is
the human embryonic carcinoma–derived NTN2/hNT
cell line.
73 These cells differentiate into neurons upon
treatment with RA and can display DA properties in
vitro,
74,75 as well as in vivo,after grafting
76,77;however,sur-
vival after grafting is usually poor and grafted animals




One additional option for stem cell treatment of PD is to
use stem cells as biological “pumps”for growth factors
or other protective agents.Stem cells can quite easily be
genetically modified to produce high amounts of such
agents and could then be grafted to either the putamen
or the substantia nigra compacta (SNc),where they could
help by protecting the remaining endogenous DA neu-
rons. It has been shown that stem cells producing glial
cell line–derived neurotrophic factor (GDNF) can
increase the survival of cocultured DA neurons
78 or
cotransplanted DA neurons.
79 In addition, C17.2 cells
producing GDNF
80 or the GDNF family member
persephin
81 can protect the remaining DA neurons in a
mouse model of PD.Since chronic injections of GDNF
have shown positive effects on parkinsonian symptoms
in a small clinical trial,
82 the delivery of GDNF using stem
cells could become an interesting treatment alternative
for PD.
Fetal midbrain dopaminergic progenitors
A possible way to compensate for the limitations in
obtaining fetal DA neurons for grafting is to try to expand
the numbers of fetal DA neurons via in vitro expansion
of mesencephalic precursor cells.Studer et al showed that
treatment of primary cultures of fetal DA neurons with
FGF2 resulted in a 30-fold increase in the number of DA
neurons in the cultures,and such neurons could reduce
rotational asymmetry after grafting in a rat model of PD.
83
In another study,Studer et al showed that the expansion
of mesencephalic precursor cells could be further
increased by culturing the neurons in low (3%) oxygen
concentration
84 or by adding ascorbic acid to the cultures.
85
Using a similar approach,the same group later described
the expansion and differentiation of human mesen-
cephalic precursor cells into DA neurons that survived
Basic research
306grafting to the rat brain.
86 One problem with this method
is that the expanded mesencephalic precursor cells show
such poor survival after grafting that most of the benefits
of the expansion step are lost.
87Another disadvantage is
that the mesencephalic precursor cells seems to lose their
ability to become DA neurons after prolonged expansion
for more than 2 to 3 weeks.A different research group led
by Carvey have used cytokines,such as IL-1,IL-11,LIF,
and GDNF,to increase DA differentiation from rat
88-90 or
human
91 mesencephalic precursor cells.Other protocols
for expansion and DA differentiation of human fetal mes-
encephalic progenitors have also been described,
67,92 but
no significant functional effects have been yet shown for
such human DA neurons.
Adult neural stem cells
For many people,the use of any kind of embryonic cells
is highly controversial and therefore the use of stem cells
derived from adult individuals has become an attractive
option.The traditional view of the nervous system used
to be that no new neurons were born in adults.This con-
cept was first challenged by Altman,
93 and later it was
shown that several regions of the adult nervous system
could give rise to new neurons,astrocytes,and oligoden-
drocytes in vitro.
65,94-96 In vivo,however,neurogenesis has
so far been considered to be restricted to the subventric-
ular zone and its projection through the rostral migratory
stream to the olfactory bulb and to dentate gyrus of the
hippocampus.
97 One interesting possibility for the treat-
ment of PD would be the occurrence of endogenous
neural stem cells residing within the vicinity of the adult
SNc or the striatal target area,which could be stimulated
to repair some of the damaged nigrostriatal circuit found
in PD.With this aim,Fallon et al described how infusion
of transforming growth factor α (TGFα) into the striatal
parenchyma resulted in an “in vivo induction of massive
proliferation,directed migration,and differentiation of
neural cells”from the subventricular zone,with positive
functional effects in a rat model of PD.
98This potentially
very interesting observation now awaits confirmation by
other independent research groups. Moreover, it was
recently suggested that there is a turnover of DA neurons
in the SNc of the adult mouse and that this turnover
increases when the DA neurons are toxically injured by
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
treatment.
99 Other workers have failed to find such a
turnover normally ongoing in the adult SNc, but it has
been shown that adult neural stem cells isolated from the
SNc region have the potential to differentiate into neu-
rons when grafted into neurogenic regions such as the
hippocampus.
100 Additional research will have to show
whether or not similar results can be found in humans.
Conclusion
The optimal source for transplantation is one of cells that
can be efficiently and reproducibly produced at a rea-
sonable cost in combination with showing predictable
therapeutic efficacy after grafting.The cells should require
minimal genetic manipulation or modification by signal-
ing molecules in culture media to properly differentiate
into the required cell types.Furthermore,they should be
nonproliferative after grafting,free of infectious elements,
and immunologically compatible with the host.
As reviewed in this article,research to develop transplant
procedures is trying to fulfill these criteria.In contrast to
the limitations of fetal cell sources,and to the cellular-
molecular complexities of diverse NPCs,advances in the
biology of blastula-derived ES cells suggest that this
source may have important advantages over the others.
However, to keep the expectations of stem cells from
becoming unrealistic,it should probably be emphasized
to clinicians and to patients and their families not to
expect the clinical outcome using stem cell–derived DA
neurons to be fundamentally “better” than what has
already been achieved in the best cases using fetal DA
neurons.After all,stem cells are basically just a way of
obtaining a more practical and reliable source of the
same type of neuron that has already been tried in 
clinics.
However,one potentially important benefit of using stem
cell–derived DA neurons,which is separate from all logis-
tical advantages,is that this is a much purer source of DA
neurons than the currently used fetal midbrain prepara-
tions,where only about 10% of the neurons are actually
DA neurons,the other 90% being primarily GABAergic
(GABA,γ-aminobutyric acid).Although fetal midbrain
cell preparations have been used extensively,very little
is known to what extent such GABAergic cells might
actually be counteracting some of the positive effects
generated by the DA neurons.In addition,the 10% DA
neurons will consist of both SNc (A9) and ventral
tegmental midbrain (VTA,A10) DA neurons.There is
selective degeneration of A9 neurons and a relative spar-
ing of A10 neurons in PD.
101-104These two subpopulations
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307of DA neurons within the SNc serve different functions
and project to different brain areas (even within the SNc
through dendritic release).The midline-positioned A10
DA neurons
105 project primarily to limbic and cortical
regions,
106 while the neighboring A9 DA neurons (which
dysfunction in PD) innervate putamen motor areas.
107
Thus,the differences between DA A10 and A9
108,109 are
significant,and it might be possible to increase the func-
tional effects of DA neuronal transplants by increasing
the proportion of A9 neurons compared with A10 neu-
rons.
110-112
Another limiting aspect of cell therapy for PD is the fact
that,in most studies,cells have been placed in the ectopic
target area and not in the SNc where the actual degen-
eration takes place.Such an ectopic placement is neces-
sary due to the very limited success of getting DA neu-
rons grafted on the SNc to exhibit long-distance growth
and show reestablishment of the nigrostriatal pathway.
The use of stem cells for generating DA neurons for
transplantation could allow for genetic or epigenetic
manipulations that facilitate target finding and long-dis-
tance growth. Another option that is currently under
investigation is grafting to multiple target areas within
the basal ganglia circuit.
113Thus,besides finding the opti-
mal cell source, there are several other areas such as
patient selection, study design, transplantation tech-
niques,target selection,and combination therapies,where
considerable improvements can be made
14,35,111 before
making the final judgment of whether cell transplanta-
tion is a useful treatment for PD. ❏
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Terapia de células madre para la enfermedad
de Parkinson
El transplante de neuronas dopaminérgicas (DA)
fetales humanas a pacientes con enfermedad de
Parkinson (EP) ha dado validez al principio según el
cual las nuevas neuronas pueden sobrevivir por al
menos una década, y después integrarse funcional-
mente y aportar un alivio sintomático significativo.
Desafortunadamente, las limitaciones éticas, técni-
cas y prácticas de utilizar neuronas DA fetales como
la fuente del transplante celular en la EP, asociadas
al desarrollo de efectos secundarios indeseables
relacionados con el transplante, ha puesto freno a
la extensión de este tratamiento a la práctica clí-
nica. Se espera que los recientes avances en los cam-
pos de la biología de células madre y en la investi-
gación de la neurogénesis en el adulto conducirán
a nuevas y desafiantes vías para una mejor com-
prensión y control de los parámetros biológicos
necesarios para realizar un reemplazo neuronal
seguro y exitoso en pacientes con EP.
Thérapie à base de cellules souches dans la
maladie de Parkinson
La transplantation de neurones dopaminergiques
(DA) humains de fœtus à des patients atteints par
la maladie de Parkinson (MP), a apporté la démons-
tration du principe selon lequel de nouveaux neu-
rones peuvent survivre pendant au moins une
décennie, et ensuite s’intégrer fonctionnellement
et apporter un soulagement symptomatique signi-
ficatif. Malheureusement, les restrictions éthiques,
techniques et pratiques à l’utilisation des neurones
DA de fœtus pour la transplantation cellulaire dans
la MP, associées au développement d’effets secon-
daires indésirables liés aux greffes, ont mis un frein
à l’extension de ce traitement en pratique clinique.
Heureusement, des avancées récentes dans les
domaines de la biologie des cellules souches et de
la recherche sur la neurogenèse de l’adulte con-
duiront à explorer de nouvelles voies passionnan-
tes pour mieux comprendre et contrôler les
paramètres biologiques nécessaires pour réaliser un
remplacement réussi et sans risque des neurones
chez les patients atteints de la MP.
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